ArticleCancers2020
Frequent
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Contribution of histone variants to aneuploidy: a cancer perspective.Frontiers in genetics · 2023Pooled it
- Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions.Cancers · 2026Review
- Identification of two genes associated with recurrence in Paget's disease and construction of a predictive model.Frontiers in genetics · 2026Article
- Insights Into Mammary and Extramammary Paget's Disease: Diagnosis, Management, and Recent Advances.Cureus · 2025Review
- Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism.British journal of cancer · 2024Article
- FOXM1: a new therapeutic target of extramammary Paget disease.Scientific reports · 2024Article
- Article
- A clinicopathological analysis of forkhead box A1 (FOXA1) and estrogen receptor alpha expression in extramammary Paget's disease.Fujita medical journal · 2023Article
- Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.Cancer science · 2022Article
- Transcriptome sequencing reveals a lncRNA-mRNA interaction network in extramammary Paget's disease.BMC medical genomics · 2021Article
- Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments.Current oncology (Toronto, Ont.) · 2021Review
- CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease.Frontiers in oncology · 2021Article
- Detection ofJournal of oncology · 2021Article
- Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.Oncogene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extramammary Paget's disease (EMPD) is a neoplastic skin disease of indeterminate origin with an unknown genetic cause. We performed a comprehensive genetic analysis or targeted gene sequencing in 48 patients with EMPD. We identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.